BioLineRx Ltd.
BLRX
$2.75
-$0.32-10.42%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.18M | -2.98M | -7.82M | -3.40M | -9.22M |
| Total Depreciation and Amortization | 441.00K | 2.24M | 2.96M | 3.26M | 3.99M |
| Total Amortization of Deferred Charges | 784.00K | 802.00K | 802.00K | 1.44M | 742.00K |
| Total Other Non-Cash Items | -9.38M | -14.32M | -14.66M | -22.10M | -17.57M |
| Change in Net Operating Assets | 1.26M | 770.00K | -2.49M | -11.56M | -21.82M |
| Cash from Operations | -8.07M | -13.48M | -21.20M | -32.36M | -43.87M |
| Capital Expenditure | -25.00K | 6.00K | 6.00K | -21.00K | -53.00K |
| Sale of Property, Plant, and Equipment | 0.00 | 0.00 | 11.00K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -8.52M | 2.94M | 9.43M | 4.53M | 29.43M |
| Cash from Investing | -8.55M | 2.95M | 9.45M | 4.51M | 29.37M |
| Total Debt Issued | -- | 0.00 | 0.00 | 19.22M | 19.22M |
| Total Debt Repaid | -5.01M | -15.86M | -15.64M | -15.30M | -14.94M |
| Issuance of Common Stock | 13.89M | 24.89M | 24.55M | 27.26M | 16.56M |
| Repurchase of Common Stock | -- | -- | -180.00K | -180.00K | -180.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 8.88M | 9.03M | 8.73M | 31.00M | 20.66M |
| Foreign Exchange rate Adjustments | 549.00K | 586.00K | 593.00K | -111.00K | 22.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -7.19M | -922.00K | -2.43M | 3.05M | 6.18M |